Yahuang Pharmaceutical (688176)
SSE · 688176
Market Cap$5.9B
Revenue$287.1M
Employees497
Listed OnSSE
Ticker688176
CEO / ExecDr. Ke Pan
HeadquartersShanghai
MarketMainland China
Websitewww.asieris.cn
Overview
Jiangsu Yahong Meditech Co., Ltd., a pharmaceutical company, focuses on urogenital tumors and women's health in China and internationally. It develops APL-1702, a photodynamic therapy product for the treatment of high-grade squamous intraepithelial lesions of the cervix, as well as for HPV virus clearance indication; APL-1706 and APLD-2304 for non-muscle invasive bladder cancer (NMIBC) diagnosis and surgery indication; APL-1202, an oral reversible MetAP2 inhibitor for untreated intermediate-risk
Data Note
This record combines exchange-directory fields with selected profile enrichment. Treat market data, leadership and financial figures as directional unless verified against company filings, exchange announcements or the issuer's own disclosures.